Published in Neurology on November 25, 2003
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol (2009) 1.48
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics (2011) 1.17
Oligodendrocyte progenitor cell numbers and migration are regulated by the zebrafish orthologs of the NF1 tumor suppressor gene. Hum Mol Genet (2010) 1.04
Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res (2012) 1.02
Inherited predisposition to glioma. Neuro Oncol (2009) 0.99
Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Childs Nerv Syst (2006) 0.98
Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst (2009) 0.97
Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I. Case Rep Med (2009) 0.89
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Glioblastoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Brain Tumor Res Treat (2014) 0.80
Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents. Nutr Cancer (2011) 0.79
Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab. J Neurol (2014) 0.79
Clinicopathologic implications of NF1 gene alterations in diffuse gliomas. Hum Pathol (2015) 0.76
A rare case of neurofibromatosis - type 1. Asian J Neurosurg (2015) 0.75
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol (2016) 0.75
CNS Tumors in Neurofibromatosis. J Clin Oncol (2017) 0.75
Human stem cell modeling in neurofibromatosis type 1 (NF1). Exp Neurol (2017) 0.75
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA (1997) 8.30
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell (1990) 8.10
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A (1992) 5.53
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (1998) 5.30
Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol (2000) 5.28
The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell (1990) 5.24
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84
Prevention of neural tube defects. Lancet (1993) 4.83
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res (2000) 4.79
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res (1996) 4.42
Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A (1990) 3.70
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol (1994) 3.66
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol (2000) 3.61
The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature (1996) 3.40
Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci U S A (1972) 3.24
Sporadic medulloblastomas contain PTCH mutations. Cancer Res (1997) 3.22
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology (1994) 3.19
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res (1991) 3.16
Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet (1999) 3.15
Appearance of T-cell markers in bone marrow rosette-forming cells after incubation with thymosin, a thymic hormone. Proc Natl Acad Sci U S A (1971) 3.13
Emulsifier of Arthrobacter RAG-1: specificity of hydrocarbon substrate. Appl Environ Microbiol (1979) 3.11
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst (2001) 2.90
17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res (2000) 2.81
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77
Adherence of Acinetobacter calcoaceticus RAG-1 to human epithelial cells and to hexadecane. Infect Immun (1981) 2.74
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol (2001) 2.34
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res (2001) 2.28
Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol (1997) 2.28
Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest (1999) 2.27
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23
Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20
Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol (1995) 2.19
Divergent orientation of transcription from the biotin locus of Escherichia coli. J Mol Biol (1971) 2.18
Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. J Neurosurg (1998) 2.17
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
PTEN mutations in gliomas and glioneuronal tumors. Oncogene (1998) 2.01
Interactions of helical polypepetide segments which span the hydrocarbon region of lipid bilayers. Studies of the gramicidin A lipid-water system. J Mol Biol (1977) 2.00
Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res (1998) 1.99
Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol (1997) 1.95
Abundant mitochondrial DNA variation and world-wide population structure in humpback whales. Proc Natl Acad Sci U S A (1993) 1.95
Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene (1999) 1.91
Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol (2001) 1.91
Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology (2002) 1.90
Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg (2001) 1.85
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene (2008) 1.84
Linkage disequilibrium in the neurofibromatosis 1 (NF1) region: implications for gene mapping. Am J Hum Genet (1993) 1.83
Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg (2000) 1.82
Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics (1995) 1.79
Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet (1983) 1.78
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res (2001) 1.77
Controls and polarity of transcription during bacteriophage T4 development. J Mol Biol (1971) 1.77
Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med (2000) 1.76
Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res (1999) 1.76
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res (1994) 1.76
Fractionation of the complementary strands of coliphage T4 DNA based on the asymmetric distribution of the poly U and poly U,G binding sites. Virology (1968) 1.75
Ontogenesis of cell-mediated immunity in murine thymocytes and spleen cells and its acceleration by thymosin, a thymic hormone. J Immunol (1971) 1.73
Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci U S A (1987) 1.71
Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am J Med Genet (2000) 1.70
Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol (1993) 1.67
The human homolog of murine Evi-2 lies between two von Recklinghausen neurofibromatosis translocations. Genomics (1990) 1.66
Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Neurology (1996) 1.66
Intramedullary cavernous angiomas of the spinal cord: clinical presentation, pathological features, and surgical management. Neurosurgery (1992) 1.65
Chromosome 14-encoded Alzheimer's disease: genetic and clinicopathological description. Ann Neurol (1994) 1.64
The phosphoprotein of the dentin matrix. Biochemistry (1967) 1.62
Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet (1994) 1.62
Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol (1998) 1.62
Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene (1994) 1.58
Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology (2003) 1.57
Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest (2000) 1.56
Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res (1995) 1.56
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology (2001) 1.54
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J (1998) 1.54
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery (1999) 1.52
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer (1994) 1.52
Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology (1997) 1.52
Rectus sheath haematoma: a new set of diagnostic features. Postgrad Med J (2002) 1.49
Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery (2000) 1.49
Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns. AJNR Am J Neuroradiol (2007) 1.48
p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res (1992) 1.48
PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res (1997) 1.47
Radiological assessment of post laryngectomy speech. Clin Radiol (1990) 1.47
NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol (2001) 1.47
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res (2001) 1.45
Population structure of nuclear and mitochondrial DNA variation among humpback whales in the North Pacific. Mol Ecol (1998) 1.44
Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res (1996) 1.44
Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc (1998) 1.44
Molecular pathways in the formation of gliomas. Glia (1995) 1.43
Orientation and control of transcription in E. coli phage lambda. Nature (1969) 1.43
Oral tocolysis with magnesium chloride: a randomized controlled prospective clinical trial. Am J Obstet Gynecol (1991) 1.41
Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene (2006) 1.41
Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts. Genomics (1990) 1.40
Prevention of neural tube defects. Lancet (1994) 1.40
Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet (2001) 1.39